ALK and neoplasm: Oral PTPN2 inhibitor ABBV‐CLS‐484 disrupts mitochondrial renewal and blocks TFRC‐mediated mitophagy to exert anti‐tumor activities, supporting clinical development for ALK+ ALCL.